Redirected chimeric antigen receptor (CAR) T-cells can acknowledge and eradicate most cancers cells in a serious histocompatibility advanced impartial method. Genetic engineering of T cells by means of CAR expression has yielded nice ends in the remedy of hematological malignancies in contrast with stable tumors.
There was a continuing effort to reinforce the effectiveness of those residing medication, attributable to their restricted success in focusing on stable tumors. Poor T cell trafficking, tumor-specific antigen choice, and the immunosuppressive tumor microenvironment are thought-about as the primary limitations in focusing on stable tumors by CAR T-cells.
Right here, we reviewed the present state of CAR T-cell remedy in breast most cancers, because the second cancer-related loss of life in ladies worldwide, in addition to some methods adopted to maintain the primary limitations of CAR T-cells beneath management. Additionally, we summarized varied approaches which have been developed to reinforce the therapeutic outcomes of this remedy in stable tumors focusing on.
The prognosis of sufferers with diffuse giant B-cell lymphoma a major refractory illness or relapsed inside 12 months after autologous hematopoietic cell transplantation is poor with a median survival of solely 6 months. With the brand new CD19-directed CAR T-cell remedy, 40% of the sufferers nonetheless obtain a long-term remission.
Nonetheless, this new remedy does convey new challenges resembling bridging the time through the CAR T-cell product time, and recognition of treatment-related unwanted effects resembling cytokine launch syndrome or neurotoxicity. Subsequently, remedy by a devoted, multidisciplinary group is critical. Future analysis will concentrate on extending CAR T-cell remedy to different illnesses and enhance remedy in non-responsiveness or resistance to CAR-T cell remedy.
Chimeric antigen receptor T cells self-neutralizing IL6 storm in sufferers with hematologic malignancy
IL6 is likely one of the most elevated cytokines throughout chimeric antigen receptor (CAR) T cell cytokine launch syndrome (CRS), and IL6R blockade by Tocilizumab has efficiently relieved essentially the most life-threatening elements of CRS in sufferers. As well as, newest research demonstrated the important function of IL1 in driving CART induced neurotoxicity in mouse fashions.
Right here we current a medical investigation of anti-CD19 and anti-BCMA CART (41BBζ) secreting an anti-IL6 scFv and IL1 receptor antagonist (IL1RA) in treating sufferers with hematologic malignancy. Our outcomes revealed that IL6 and IL1B had been maintained at low ranges with out important elevation throughout CRS, rendering Tocilizumab dispensable.
Furthermore, handled sufferers didn’t present neurotoxicity throughout CRS and exhibited delicate to average CRS. Notably, we noticed excessive price of full response (CR) and important CART growth throughout remedy. In sum, we conclude that CART-secreting anti-IL6 scFv and IL1RA may self-neutralize IL6 storm and keep low ranges of IL1B throughout CART remedy to reduce IL6- and IL1-associated cytokine toxicity and neurotoxicity with out impairing therapeutic efficacy.
The power of a T cell to acknowledge international peptides is outlined by a single α and a single β hypervariable complementarity figuring out area (CDR3), which collectively kind the T cell receptor (TCR) heterodimer. In ∼30%-35% of T cells, two α chains are expressed on the mRNA stage however just one α chain is a part of the useful TCR. This impact can be noticed for β chains, though it’s much less widespread. The identification of useful α/β chain pairs is instrumental in high-throughput characterization of therapeutic TCRs.
TCRpair is the primary methodology that predicts whether or not an α and β chain pair types a useful, HLA-A*02:01 particular TCR with out requiring the sequence of a acknowledged peptide. By taking further amino acids flanking the CDR3 areas under consideration, TCRpair achieves an AUC of 0.71.
Characterization of the Therapeutic Results of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on A number of Myeloma
A number of myeloma (MM) is a tumor kind characterised by the unregulated proliferation of clonal plasma cells within the bone marrow. Immunotherapy primarily based on chimeric antigen receptor T cell (CAR-T) remedy has achieved thrilling success within the remedy of hematological malignant tumors. CD38 is very and evenly expressed in MM and is a gorgeous goal for MM remedy.
Right here, we efficiently constructed two novel second-generation CAR-T cells focusing on CD38 by retroviral vector transduction. CD38 CAR-T cells might be activated successfully after stimulation with CD38-positive tumor cells and secrete cytokines resembling IFN-γ and TNF-α to advertise tumor cell apoptosis in in vitro experiments. Actual-time fluorescence monitoring experiments
luciferase detection experiments and stream cytometry experiments revealed the environment friendly and particular killing talents of CD38 CAR-T cells towards CD38-positive tumor cells. The proliferation skill of CD38 CAR-T cells in vitro was increased than that of untransduced T cells. Additional antitumor experiments in vivo confirmed that CD38 CAR-T cells might be shortly activated to secrete IFN-γ and get rid of tumors. Thus, novel CD38-targeted second-generation CAR-T cells have environment friendly and particular antitumor exercise and will grow to be a novel remedy for the medical remedy of MM.
Liver X receptor beta deficiency attenuates autoimmune-associated neuroinflammation in a T cell-dependent method
The initiation and development of autoimmune problems resembling a number of sclerosis (MS) is linked to aberrant ldl cholesterol metabolism and overt irritation. Liver X receptors (LXR) are nuclear receptors that perform on the crossroads of ldl cholesterol metabolism and immunity, and their activation is taken into account a promising therapeutic technique to attenuate autoimmunity.
Nonetheless, regardless of clear useful heterogeneity and cell-specific expression profiles, the influence of the person LXR isoforms on autoimmunity stays poorly understood. Right here, we present that LXRα and LXRβ have an reverse influence on immune cell perform and illness severity within the experimental autoimmune encephalomyelitis mannequin, an experimental MS mannequin.
Whereas Lxrα deficiency aggravated illness pathology and severity, absence of Lxrβ was protecting. Guided by stream cytometry and through the use of cell-specific knockout fashions, lowered illness severity in Lxrβ-deficient mice was primarily attributed to modifications in peripheral T cell physiology and occurred impartial from alterations in microglia perform.
 Recombinant mouse Prostate stem cell antigen |
|
MBS9422457-05mg |
MyBiosource |
0.5mg |
EUR 1655 |
Recombinant mouse Prostate stem cell antigen |
|
MBS9422457-5x05mg |
MyBiosource |
5x0.5mg |
EUR 7290 |
 Mouse Prostate Stem Cell Antigen ELISA Kit |
|
MBS057229-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Mouse Prostate Stem Cell Antigen ELISA Kit |
|
MBS057229-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Mouse Prostate Stem Cell Antigen ELISA Kit |
|
MBS057229-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Mouse Prostate Stem Cell Antigen ELISA Kit |
|
MBS057229-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 Mouse Prostate stem cell antigen ELISA Kit |
|
MBS289860-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 4630 |
Mouse Prostate stem cell antigen ELISA Kit |
|
MBS289860-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 440 |
Mouse Prostate stem cell antigen ELISA Kit |
|
MBS289860-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2480 |
Mouse Prostate stem cell antigen ELISA Kit |
|
MBS289860-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 580 |
) Recombinant Mouse Prostate stem cell antigen(Psca) |
|
AP72740 |
SAB |
each |
Ask for price |
|
|
) Recombinant Mouse Prostate stem cell antigen (Psca) |
|
CSB-YP018840MO |
Cusabio |
5939 mg |
Ask for price |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
CSB-YP018840MO-20ug |
Cusabio |
20ug |
Ask for price |
|
|
|
Description: 21-95aa |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
MBS962351-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 320 |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
MBS962351-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 515 |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
MBS962351-05mgYeast |
MyBiosource |
0.5mg(Yeast) |
EUR 1260 |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
MBS962351-5x05mgYeast |
MyBiosource |
5x0.5mg(Yeast) |
EUR 5485 |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
RPC20241-100ug |
Biomatik Corporation |
100ug |
EUR 569.8 |
Recombinant Mouse Prostate stem cell antigen (Psca) |
|
RPC20241-20ug |
Biomatik Corporation |
20ug |
EUR 353.4 |
) StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|
CBA-325 |
Cell Biolabs |
96 assays |
EUR 1027.2 |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|
CBA-325-5 |
Cell Biolabs |
5 x 96 assays |
EUR 4033.2 |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
) HESCA-1 (Human Embryonic Stem Cell Antigen-1) |
|
MBS604449-01mg |
MyBiosource |
0.1mg |
EUR 785 |
HESCA-1 (Human Embryonic Stem Cell Antigen-1) |
|
MBS604449-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3385 |
 ELISA Kit for Mouse Prostate stem cell antigen |
|
E8693m |
EIAab |
96T |
EUR 441.6 |
 ELISA Kit) Mouse Prostate stem cell antigen (PSCA) ELISA Kit |
|
abx520719-96tests |
Abbexa |
96 tests |
EUR 687.5 |
|
|
 Mouse Psca/ Prostate stem cell antigen ELISA Kit |
|
E1215Mo |
Sunlong |
1 Kit |
EUR 543 |
|
|
 Mouse Prostate stem cell antigen, Psca ELISA KIT |
|
ELI-22375m |
Lifescience Market |
96 Tests |
EUR 1038 |
Mouse Prostate stem cell antigen (PSCA) ELISA Kit |
|
RK13577 |
Abclonal |
96T |
EUR 322.37 |
 LY6E/Stem cell antigen 1 Polyclonal Antibody |
|
MBS9236660-01mL |
MyBiosource |
0.1mL |
EUR 415 |
LY6E/Stem cell antigen 1 Polyclonal Antibody |
|
MBS9236660-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1841 |
 StemTAG PCR Primer Set for Stem Cell Characterization |
|
CBA-303 |
Cell Biolabs |
1 kit |
EUR 470.4 |
|
Description: StemTAG PCR Primer Set for Stem Cell Characterization includes 7 primer pairs: Oct-4, NANOG, AFP, Flk-1, and NCAM, plus GAPDH and beta-actin as controls. |
 Prostate stem cell antigen |
|
AP86675 |
SAB |
1mg |
EUR 2640 |
|
|
Prostate stem cell antigen |
|
AP87071 |
SAB |
1mg |
EUR 2640 |
|
|
) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) |
|
MBS630318-01mg |
MyBiosource |
0.1mg |
EUR 665 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) |
|
MBS630318-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2850 |
 Total Protein - Murine Embryonic Stem Cell Line D3 |
|
CBA-305 |
Cell Biolabs |
500 ?g |
EUR 414 |
Description: - Isolated from mouse ES-D3 cell line
- Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer
|
 OPCA01291-20UG - Recombinant Mouse Prostate stem cell antigen |
|
OPCA01291-20UG |
Aviva Systems Biology |
20ug |
EUR 315 |
|
|
 OPCA01291-100UG - Recombinant Mouse Prostate stem cell antigen |
|
OPCA01291-100UG |
Aviva Systems Biology |
100ug |
EUR 462 |
|
|
 OPCA01291-500UG - Recombinant Mouse Prostate stem cell antigen |
|
OPCA01291-500UG |
Aviva Systems Biology |
500ug |
EUR 1276 |
|
|
 (AP)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (AP) |
|
MBS6485594-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (AP) |
|
MBS6485594-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 APC) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) APC |
|
MBS6485595-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) APC |
|
MBS6485595-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (FITC)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (FITC) |
|
MBS6485597-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (FITC) |
|
MBS6485597-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (HRP)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (HRP) |
|
MBS6485598-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (HRP) |
|
MBS6485598-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (PE)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (PE) |
|
MBS6485604-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (PE) |
|
MBS6485604-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (Biotin)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (Biotin) |
|
MBS6485596-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (Biotin) |
|
MBS6485596-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (MaxLight 405)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 405) |
|
MBS6485599-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 405) |
|
MBS6485599-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (MaxLight 490)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 490) |
|
MBS6485600-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 490) |
|
MBS6485600-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (MaxLight 550)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 550) |
|
MBS6485601-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 550) |
|
MBS6485601-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (MaxLight 650)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 650) |
|
MBS6485602-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 650) |
|
MBS6485602-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 (MaxLight 750)) LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 750) |
|
MBS6485603-01mL |
MyBiosource |
0.1mL |
EUR 920 |
LY6E (Lymphocyte Antigen 6E, Ly-6E, Retinoic Acid-induced Gene E Protein, RIG-E, Stem Cell Antigen 2, SCA-2, Thymic Shared Antigen 1, TSA-1, 9804, RIGE, SCA2, TSA1) (MaxLight 750) |
|
MBS6485603-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3990 |
 ELISA Kit) CytoSelect Proliferating Cell Nuclear Antigen (PCNA) ELISA Kit |
|
CBA-254 |
Cell Biolabs |
96 assays |
EUR 672 |
|
Description: Cell Biolabs? CytoSelect Proliferating Cell Nuclear Antigen (PCNA) ELISA Kit is an enzyme immunoassay developed for the detection and quantitation of PCNA from nuclear and whole cell extracts. The kit detects PCNA from mouse, rat and human, and has a detection sensitivity limit of 12.5 ng/mLPCNA. Each kit provides sufficient reagents to perform up to 96 assays including standard curve and unknown samples. |
 Prostate Stem Cell Antigen Antibody |
|
8C0310 |
AAT Bioquest |
50ug |
EUR 368 |
|
Description: Prostate Stem Cell Antigen Antibody |
Prostate Stem Cell Antigen Antibody |
|
33476 |
SAB |
100ul |
EUR 319 |
Prostate Stem Cell Antigen Antibody |
|
33476-100ul |
SAB |
100ul |
EUR 302.4 |
Prostate Stem Cell Antigen Antibody |
|
33476-50ul |
SAB |
50ul |
EUR 224.4 |
Prostate Stem Cell Antigen Antibody |
|
DF8709 |
Affbiotech |
200ul |
EUR 420 |
Prostate Stem Cell Antigen Antibody |
|
DF8709-100ul |
Affinity Biosciences |
100ul |
EUR 168 |
|
|
|
Description: WB,IF/ICC,ELISA(peptide) |
Prostate Stem Cell Antigen Antibody |
|
DF8709-200ul |
Affinity Biosciences |
200ul |
EUR 210 |
|
|
|
Description: WB,IF/ICC,ELISA(peptide) |
Prostate Stem Cell Antigen Antibody |
|
E033476 |
EnoGene |
100μg/100μl |
EUR 255 |
|
Description: Available in various conjugation types. |
Prostate Stem Cell Antigen Antibody |
|
E11-0310C |
EnoGene |
100μg/100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
Prostate Stem Cell Antigen Antibody |
|
E19-8709-1 |
EnoGene |
50ug/50ul |
EUR 145 |
|
Description: Available in various conjugation types. |
Prostate Stem Cell Antigen Antibody |
|
E19-8709-2 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Prostate Stem Cell Antigen Antibody |
|
MBS853379-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Prostate Stem Cell Antigen Antibody |
|
MBS853379-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS853379-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS853379-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS853379-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS8532743-005mg |
MyBiosource |
0.05mg |
EUR 235 |
Prostate Stem Cell Antigen Antibody |
|
MBS8532743-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Prostate Stem Cell Antigen Antibody |
|
MBS8532743-01mLAF405M |
MyBiosource |
0.1mL(AF405M) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS8532743-01mLAF546 |
MyBiosource |
0.1mL(AF546) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS8532743-01mLAF750 |
MyBiosource |
0.1mL(AF750) |
EUR 465 |
Prostate Stem Cell Antigen Antibody |
|
MBS9400891-005mL |
MyBiosource |
0.05mL |
EUR 245 |
Prostate Stem Cell Antigen Antibody |
|
MBS9400891-01mL |
MyBiosource |
0.1mL |
EUR 305 |
Prostate Stem Cell Antigen Antibody |
|
MBS9400891-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1230 |
Prostate Stem Cell Antigen Antibody |
|
MBS9504710-005mL |
MyBiosource |
0.05mL |
EUR 285 |
Prostate Stem Cell Antigen Antibody |
|
MBS9504710-01mL |
MyBiosource |
0.1mL |
EUR 385 |
Prostate Stem Cell Antigen Antibody |
|
MBS9504710-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1590 |
Prostate Stem Cell Antigen Antibody |
|
MBS9510061-005mL |
MyBiosource |
0.05mL |
EUR 285 |
Prostate Stem Cell Antigen Antibody |
|
MBS9510061-01mL |
MyBiosource |
0.1mL |
EUR 385 |
Prostate Stem Cell Antigen Antibody |
|
MBS9510061-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1590 |
Prostate Stem Cell Antigen Antibody |
|
MBS9609026-01mL |
MyBiosource |
0.1mL |
EUR 260 |
Prostate Stem Cell Antigen Antibody |
|
MBS9609026-02mL |
MyBiosource |
0.2mL |
EUR 305 |
Prostate Stem Cell Antigen Antibody |
|
MBS9609026-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-1mg |
|
QP9353-ye-1mg |
EnQuireBio |
1mg |
EUR 2763.6 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-100ug |
|
QP9353-ye-100ug |
EnQuireBio |
100ug |
EUR 685.2 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-10ug |
|
QP9353-ye-10ug |
EnQuireBio |
10ug |
EUR 326.4 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-200ug |
|
QP9353-ye-200ug |
EnQuireBio |
200ug |
EUR 1077.6 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-500ug |
|
QP9353-ye-500ug |
EnQuireBio |
500ug |
EUR 1806 |
 Recombinant Mouse Prostate stem cell antigen Protein, His, Yeast-50ug |
|
QP9353-ye-50ug |
EnQuireBio |
50ug |
EUR 424.8 |
 (AP)) Ly-6A/E (Ly6A/E, Lymphocyte Antigen 6A-2/6E-1, Ly-6A.2/Ly-6E.1, Ly6a, Ly6, Ly-6A.2, Ly-6E.1, Stem Cell Antigen 1, Sca1, SCA-1, T-cell-activating Protein, TAP, Lymphocyte Activation Protein 6) (AP) |
|
MBS6248099-01mL |
MyBiosource |
0.1(mL |
EUR 995 |
Ly-6A/E (Ly6A/E, Lymphocyte Antigen 6A-2/6E-1, Ly-6A.2/Ly-6E.1, Ly6a, Ly6, Ly-6A.2, Ly-6E.1, Stem Cell Antigen 1, Sca1, SCA-1, T-cell-activating Protein, TAP, Lymphocyte Activation Protein 6) (AP) |
|
MBS6248099-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4325 |
 Antibody) Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx008545 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx004291-100l |
Abbexa |
100 µl |
EUR 400 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx004291-20l |
Abbexa |
20 µl |
EUR 175 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx004291-50l |
Abbexa |
50 µl |
EUR 275 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx013183-100g |
Abbexa |
100 µg |
EUR 237.5 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx013183 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 100 ug
- 200 ug
- 300 µg
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx013183-10g |
Abbexa |
10 µg |
EUR 43.75 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx013183-200g |
Abbexa |
200 µg |
EUR 312.5 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx027872-400l |
Abbexa |
400 µl |
EUR 518.75 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx027872-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx027872-80l |
Abbexa |
80 µl |
EUR 250 |
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx132387-01mg |
Abbexa |
0.1 mg |
EUR 275 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx132387 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx114737-100l |
Abbexa |
100 µl |
EUR 612.5 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx114737 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102687-100l |
Abbexa |
100 µl |
EUR 275 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx102687 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102687-1ml |
Abbexa |
1 ml |
EUR 750 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102687-200l |
Abbexa |
200 µl |
EUR 337.5 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102688-100l |
Abbexa |
100 µl |
EUR 275 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx102688 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102688-1ml |
Abbexa |
1 ml |
EUR 750 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx102688-200l |
Abbexa |
200 µl |
EUR 337.5 |
 Antibody) Prostate stem cell antigen (PSCA) Antibody |
|
abx331721-100ul |
Abbexa |
100 ul |
EUR 510 |
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx320478-100l |
Abbexa |
100 µl |
EUR 350 |
Prostate Stem Cell Antigen (PSCA) Antibody |
|
20-abx320478 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Prostate Stem Cell Antigen (PSCA) Antibody |
|
abx320478-50l |
Abbexa |
50 µl |
EUR 237.5 |
Prostate stem cell antigen (PSCA) Antibody |
|
abx325516-100g |
Abbexa |
100 µg |
EUR 250 |
Prostate stem cell antigen (PSCA) Antibody |
|
20-abx325516 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Prostate stem cell antigen (PSCA) Antibody |
|
abx325516-50g |
Abbexa |
50 µg |
EUR 187.5 |
Collectively, our findings point out that LXR isoforms play functionally non-redundant roles in autoimmunity, doubtlessly having broad implications for the event of LXR-based therapeutic methods aimed toward dampening autoimmunity and neuroinflammation.
